Clinical trial
The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at…
NCT00212823 · Ortho-McNeil Neurologics, Inc., Industry · Completed
Key facts
| NCT number | NCT00212823 |
|---|---|
| Title | The Effectiveness of Almotriptan Malate (AXERT®) 12.5 Milligrams When Taken at the Onset of Migraine Pain |
| Official title | AXERT® 12.5mg Time vs Intensity Migraine Study (AIMS): An Open-label Multicenter Trial to Evaluate the Efficacy of Almotriptan Malate (AXERT®) 12.5 Milligram Intervention at Onset of Migraine Pain |
| Lead sponsor | Ortho-McNeil Neurologics, Inc., Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Migraine |
| Intervention type | Drug |
| Interventions | almotriptan malate |
| Enrollment | 1,450 |
| Start date | Jun 1, 2004 |
| Completion | Feb 1, 2005 |
| First posted | Sep 21, 2005 |
| Last update posted | May 19, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: